Resident doctor at University of Florence; University of Hertfordshire,Italy
Davide Arillotta, MD, is a dynamic psychiatrist from Torino, Italy, with a strong passion for life sciences and mental health. Throughout his career, Dr. Arillotta has focused on substance use disorders, clinical toxicology, and the intersection of mental health and addiction. His work spans across clinical settings, research, and harm reduction initiatives, making significant contributions to both local and international communities.
professional profile
scopus
🎓 Education
Dr. Arillotta holds a Master’s Degree in Medicine and Surgery (2014) from the University of Turin, Italy, where he also completed his psychiatric residency (2015-2019) at the University of Catania. He is currently enrolled in a Master’s programme in Cognitive Psychotherapy at Centro Clinico Crocetta, Turin. His academic journey includes several international experiences, including studies in Coimbra, Portugal, and research placements in the UK.
💼 Work Experience
Dr. Arillotta has served as a Clinical Toxicology Resident at the University of Florence since November 2021. He has extensive experience as a psychiatrist with various institutions, including NHS Trusts in Italy. He also worked as a freelance psychiatrist and collaborated on harm reduction projects in leisure environments. His clinical work spans general psychiatry, dual diagnosis, and substance use disorders.
🧠 Skills
Dr. Arillotta possesses expertise in clinical toxicology, psychiatric care, and cognitive psychotherapy. He is skilled in the application of harm reduction strategies, tapering/switching protocols for chronic pain, and has significant experience in research and clinical trials related to novel psychoactive substances.
🏆 Awards and Honors
Dr. Arillotta has been recognized for his outstanding contributions, winning the poster competition at the “New Challenges in Psychiatry” conference in Rome (2019) and securing a scholarship for a development cooperation project in Burkina Faso (2015).
👥 Memberships and Affiliations
He is affiliated with the Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit at the University of Hertfordshire, UK. Additionally, he was a delegate at the European Forum of Psychiatric Trainees (EFPT) in 2018.
📚 Teaching and Mentorship
Dr. Arillotta has contributed to the training of medical students and psychiatric trainees through workshops and scientific courses. His teaching is enhanced by his diverse clinical and research experiences, particularly in the fields of neuroethics and toxicology.
🔬 Research Focus
Dr. Arillotta’s research is centered on the psychopathological dimensions of substance abuse, biomarkers associated with cravings, and the adverse health effects of novel psychoactive substances like MDPHP. He is also exploring the potential impact of GLP-1 receptor agonists on mental health and addiction.
publication
- “Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach”
- 🗓 Year: 2024
- 📜 Journal: Brain Sciences
- 🔬 Topic: GLP-1 Receptor Agonists and their impact on substance use, compulsive behavior, and libido.
- 🌐 Method: Mixed-Methods and Social Media Analysis
- “Exploring the Association Between Suicidal Thoughts, Self-Injury, and GLP-1 Receptor Agonists in Weight Loss Treatments: Insights from Pharmacovigilance Measures and Unmasking Analysis”
- 🗓 Year: 2024
- 📜 Journal: European Neuropsychopharmacology
- 🔬 Topic: Suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments.
- 🚨 Focus: Pharmacovigilance and risk analysis
- “Clinical Manifestations and Analytical Reports for MDPHP Acute Intoxication Cases”
- 🗓 Year: 2024
- 📜 Journal: Journal of Pharmaceutical and Biomedical Analysis
- 🔬 Topic: MDPHP acute intoxication and clinical manifestations.
- 💉 Focus: Toxicology and substance abuse
- “Semaglutide as a Possible Calmodulin Binder: Ligand-Based Computational Analyses and Relevance to Its Associated Reward and Appetitive Behaviour Actions”
- 🗓 Year: 2024
- 📜 Journal: Scientia Pharmaceutica
- 🔬 Topic: Semaglutide, calmodulin binding, and its effects on reward and behavior.
- 🧠 Focus: Computational analysis and psychopharmacology
- “GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach”
- 🗓 Year: 2023
- 📜 Journal: Brain Sciences
- 🔬 Topic: Mental health effects of GLP-1 receptor agonists.
- 🌐 Method: Social media and mixed-methods analysis
- “Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?”
- 🗓 Year: 2023
- 📜 Journal: Pharmaceuticals
- 🔬 Topic: Psilocybin as a treatment for depression.
- 🍄 Focus: Psychedelics and mental health
- “Covid-19 Pandemic Impact on Substance Misuse: A Social Media Listening, Mixed Method Analysis”
- 🗓 Year: 2021
- 📜 Journal: Brain Sciences
- 🔬 Topic: Impact of Covid-19 on substance misuse.
- 🦠 Focus: Social media analysis and substance use during the pandemic